Related Experiment Videos
Immune hemolytic anemia associated with teicoplanin
Elena Coluccio1, M Antonietta Villa, Emmanuel Villa
1Centro Transfusionale e di Immunologia dei Transplanti, IRCCS Ospedale Maggiore, Milan, Italy. ecoluccio@yahoo.it
Transfusion
|December 25, 2003
Summary
Teicoplanin, an antibiotic, can cause immune hemolytic anemia. This case report details a patient who developed this condition after teicoplanin treatment, highlighting a rare adverse drug reaction.
Area of Science:
- Hematology
- Pharmacology
- Immunology
Background:
- Immune hemolytic anemia (IHA) is a serious condition that can be triggered by various medications.
- Drug-induced IHA presents a diagnostic challenge due to diverse clinical manifestations and antibody specificities.
Observation:
- A 68-year-old male developed worsening anemia post-reoperation for coronary artery bypass grafting.
- Medications administered during the second admission included gentamycin, teicoplanin, paracetamol, and codeine.
- The patient exhibited a positive direct antiglobulin test (DAT) for complement and IgG.
Findings:
- Autoanti-e specificity was identified in the patient's serum.
- Red blood cells (RBCs) reacted with the patient's serum specifically in the presence of teicoplanin.
- This reactivity pattern suggests teicoplanin-induced autoanti-e antibody formation leading to IHA.
Implications:
- This case represents the first documented instance of teicoplanin-induced immune hemolytic anemia.
- Clinicians should consider teicoplanin as a potential cause of IHA in patients presenting with unexplained anemia.
- Further investigation into the immunogenic properties of teicoplanin is warranted.